Population pharmacokinetics and dose–response relationships of mitoxantrone in children with acute myeloid leukaemia
This study provides novel insights into the pharmacokinetics of mitoxantrone in children. Infant patients receiving body weight-based dosing regimens may be at risk of suboptimal drug exposure, and many of these patients may tolerate higher mitoxantrone doses in line with older children. This trial was registered with the EU Clinical Trials Register (EudraCT number 2014-005066-30).
Authors
- Andrew S. Moore (ORCID: https://orcid.org/0000-0001-8062-1779)
- Arnaud Petit (ORCID: https://orcid.org/0000-0001-8363-1622)
- Hinke Siebinga (ORCID: https://orcid.org/0000-0001-7767-0393)
- Pamela R. Kearns (ORCID: https://orcid.org/0000-0003-2756-5813)
- Andrew M. Brandon (ORCID: https://orcid.org/0000-0001-6330-830X)
- S. Barnett (ORCID: https://orcid.org/0000-0002-2808-5590)
- O. P. Smith
- Nicholas Heaney
- Alwin D. R. Huitema
- Kayode Ogungbenro
- Gareth J. Veal
- Brenda Gibson
- Paul Wetherell
- André Baruchel
Institutions
- Utrecht University (NL)
- Royal Hospital for Children (GB)
- University of Manchester (GB)
- The Netherlands Cancer Institute (NL)
- University Medical Center Utrecht (NL)
- Sorbonne Université (FR)
- Hôpital Armand-Trousseau (FR)
- Assistance Publique – Hôpitaux de Paris (FR)
- Oncode Institute (NL)
- Hôpital Robert-Debré (FR)
- Princess Máxima Center (NL)
- Cancer Research UK Clinical Trials Unit (GB)
- Our Lady's Hospital (IE)
- Children's Health Queensland Hospital and Health Service (AU)
- Newcastle University (GB)
Publication Details
- Journal
- British Journal of Clinical Pharmacology
- Published
- 2026-01-14
- DOI
- https://doi.org/10.1002/bcp.70436
- Primary Topic
- Cancer Treatment and Pharmacology
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- Cancer Research UK